RESEARCHER PROFILE
Y. Benhamou
← Back to Université de Rouen Normandie
Y
Université de Rouen Normandie
Y. Benhamou works in Vasculitis and related conditions, Blood Coagulation and Thrombosis Mechanisms, Complement system in diseases, Venous Thromboembolism Diagnosis and Management, Platelet Disorders and Treatments. Recorded institutional associations include Inserm, Hôpital Charles-Nicolle, Normandie Université.
374Publications
5,398Citations
40H-index
Inclusion identifies researchers whose recorded research contributions may inform their university’s understanding of its research community. It does not rank individual research quality or establish current employment.
Selected research works
Up to 100 highly cited works; DOI links open the original research. Counts reflect the collected record, not real-time citation totals.
Epidemiology and pathophysiology of adulthood-onset thrombotic microangiopathy with severe ADAMTS13 deficiency (thrombotic thrombocytopenic purpura): a cross-sectional analysis of the French national registry for thrombotic microangiopathy
2016 · 317 citationsCOVID-19 outcomes in patients with inflammatory rheumatic and musculoskeletal diseases treated with rituximab: a cohort study
2021 · 273 citationsLong-Term Outcomes and Prognostic Factors of Complications in Takayasu Arteritis
2017 · 253 citationsPreemptive rituximab infusions after remission efficiently prevent relapses in acquired thrombotic thrombocytopenic purpura
2014 · 193 citationsA regimen with caplacizumab, immunosuppression, and plasma exchange prevents unfavorable outcomes in immune-mediated TTP
2020 · 190 citationsManagement of giant cell arteritis: Recommendations of the French Study Group for Large Vessel Vasculitis (GEFA)
2016 · 188 citationsPreemptive rituximab prevents long-term relapses in immune-mediated thrombotic thrombocytopenic purpura
2018 · 168 citationsTriaging acute pulmonary embolism for home treatment by Hestia or simplified PESI criteria: the HOME-PE randomized trial
2021 · 162 citationsDevelopment and validation of a predictive model for death in acquired severe ADAMTS13 deficiency-associated idiopathic thrombotic thrombocytopenic purpura: the French TMA Reference Center experience
2012 · 159 citationsCardiac troponin‐I on diagnosis predicts early death and refractoriness in acquired thrombotic thrombocytopenic purpura. Experience of the French Thrombotic Microangiopathies Reference Center
2014 · 141 citationsFacebook activity of residents and fellows and its impact on the doctor–patient relationship
2010 · 138 citationsRecommandations de bonne pratique pour la prise en charge de la maladie veineuse thromboembolique chez l’adulte. Version courte
2019 · 136 citationsOverall survival and mortality risk factors in Takayasu's arteritis: A multicenter study of 318 patients
2018 · 105 citationsExtended treatment of venous thromboembolism with reduced-dose versus full-dose direct oral anticoagulants in patients at high risk of recurrence: a non-inferiority, multicentre, randomised, open-label, blinded endpoint trial
2025 · 96 citationsOpen ADAMTS13, induced by antibodies, is a biomarker for subclinical immune-mediated thrombotic thrombocytopenic purpura
2020 · 76 citationsHydroxychloroquine reverses the prothrombotic state in a mouse model of antiphospholipid syndrome: Role of reduced inflammation and endothelial dysfunction
2019 · 74 citationsAdult-onset renal thrombotic microangiopathy and pulmonary arterial hypertension in cobalamin C deficiency
2015 · 73 citationsSerious infections in patients with VEXAS syndrome: data from the French VEXAS registry
2023 · 72 citationsEfficacy and safety of targeted therapies in VEXAS syndrome: retrospective study from the FRENVEX
2024 · 71 citationsDigital Ischemia Associated With Cancer
2014 · 66 citationsImmune thrombotic thrombocytopenic purpura in older patients: prognosis and long-term survival
2019 · 63 citationsEfficacy and safety of TNF-α antagonists and tocilizumab in Takayasu arteritis: multicentre retrospective study of 209 patients
2021 · 59 citationsRole of Toll‐like Receptors 2 and 4 in Mediating Endothelial Dysfunction and Arterial Remodeling in Primary Arterial Antiphospholipid Syndrome
2014 · 58 citationsRituximab as maintenance therapy for ANCA-associated vasculitides: pooled analysis and long-term outcome of 277 patients included in the MAINRITSAN trials
2023 · 54 citationsCaplacizumab use in immune-mediated thrombotic thrombocytopenic purpura: an international multicentre retrospective Cohort study (The Capla 1000+ project)
2025 · 52 citations